Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens-Reference-Cited by-同舟云学术

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Published:2017-02-27 Issue:7 Volume:89 Page:1248-1254
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Akuta Norio¹^ORCID,Sezaki Hitomi¹,Suzuki Fumitaka¹,Fujiyama Shunichiro¹,Kawamura Yusuke¹,Hosaka Tetsuya¹,Kobayashi Masahiro¹,Kobayashi Mariko²,Saitoh Satoshi¹,Suzuki Yoshiyuki¹,Arase Yasuji¹,Ikeda Kenji¹,Kumada Hiromitsu¹

Affiliation:

1. Department of Hepatology; Toranomon Hospital; Okinaka Memorial Institute for Medical Research; Tokyo Japan

2. Liver Research Laboratory; Toranomon Hospital; Tokyo Japan

Funder

Ministry of Health, Labour and Welfare, Japan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jmv.24767/fullpdf

Reference13 articles.

1. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

2. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

3. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014

4. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial;Mizokami;Lancet Infect Dis,2015

5. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir;Karino;J Hepatol,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

2. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals;The Korean Journal of Gastroenterology;2021-02-25

3. Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure;Hepatology Research;2019-12-19

4. NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors;Seminars in Liver Disease;2019-12-13

5. Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis;Internal Medicine;2019-09-15